Background
==========

Type 1 diabetes (T1D) is thought to result from an immune-mediated destruction of the pancreatic beta-cells in genetically susceptible people. The risk for developing T1 D seems to increase with genetic susceptibility in combination with the presence of immunological markers of beta-cell autoimmunity. Although the destruction of the pancreatic beta-cell is perceived to be mediated by T cells, the loss of immunological self-tolerance may result in autoantibody formation. Signs of immunological activity directed against the pancreatic beta-cell may appear many years before clinical disease presentation and predict the progression to type T1 D. Although not directly involved in beta-cell death, autoantibodies can be used as markers of beta-cell destruction and reflect disease severity. A subclass of T1 D children does not show any of these signs of humoral autoimmunity and are considered to have idiopathic or Type 1 B diabetes. Children and adolescents with newly diagnosed type 1 diabetes are more likely to present with several autoantibodies than adults, probably reflecting a stronger autoimmune state and a more severe disease progression.

Recently, there have been substantial improvements in molecular genetic diagnostics of diabetes in infants. A molecular diagnosis is now possible for glucokinase deficiency (1), mutations in transcription factors HNF-1α (2) or HNF-4 α (3), insulin gene mutations (4), and mutations in the pancreatic ATP-sensitive potassium (K-ATP) channel subunits KIR6.2 (5) and SUR1 (6, 7). Since oral treatment with sulfonylurea has become an attractive alternative for most of these patients, efforts should be made to diagnose these defects in patients with absence of autoantibodies against pancreatic antigens (8, 9, 10).

The aims of the present study were: 1) to compare the disease progression of type 1 diabetes among children negative and children positive for ICA, GADA and IA-2A, (subsequently referred to as autoantibody negative and autoantibody positive) during the first 12 months after disease onset, and 2) to investigate whether mutations in the *KCNJ11*, *ABCC8*, *HNF1A, HNF4A*or *INS*genes are common in children and adolescents with AAB negative diabetes.

Methods
=======

Subjects
--------

This is a multicenter longitudinal investigation with 18 participating pediatric centers from 15 countries in Europe and Japan. A total of 261 children and adolescents (132 girls, 129 boys, 84% Caucasian, 16% other ethnicities) up to 16 years of age were followed for 12 months from the diagnosis of T1D: Clinical information on demographics and anthropometry, insulin therapy as well as blood samples for centralized measurement of HbA~1c~and meal-stimulated C-peptide, proinsulin, and GLP-1 were collected prospectively. Exclusion criteria were: clinically suspected type 2 diabetes, diabetes in 3 consecutive generations with onset before age 25 (to exclude maturity onset diabetes of the young (MODY)), secondary diabetes, decline of enrolment into the study, and patients initially treated outside the centers for more than 5 days. Insulin regimens were recorded 1, 3, 6, 9 and 12 months after diagnosis. After 12 months, 52.9% of the children were on twice insulin daily. Only three children used an insulin infusion pump while 13% were treated with a rapid acting insulin analogue. Daily insulin dose was 0.72 ± 0.28 IU/kg (mean ± SD).

The study was performed according to the criteria of the Helsinki II Declaration and was approved by the local ethical committee in each centre. All patients, their parents or guardians gave written informed consent.

Glycemic control
----------------

Glycemic control as assessed by HbA~1c~was measured at diagnosis, and at 1, 3, 6, 9 and 12 months after diagnosis. HbA~1c~was determined centrally by ion-exchange high-performance liquid chromatography (reference range 4.1-6.4%) at Steno Diabetes Center, Gentofte, Denmark. We used insulin dose adjusted **HbA1c (IDAA1c) = HbA1c (%) + \[4 × insulin dose (U/Kg/24h)\]**as a marker of disease severity. This measure, adjusting for the exogenous insulin, reflects the underlying and theoretically untreated disease, as it mimics a situation in which no insulin was administered. In this setting it therefore reflects the severity of the disease and hence is superior to the HbA~1c~alone (11).

Antibodies
----------

As all patients were treated with insulin during the first month after diagnosis, secondary insulin antibodies (IA) could not be distinguished from primary insulin autoantibodies (IAA) and, therefore, were not included in the classification of the antibody pattern at 1 month. Patients with detectable antibodies (IA-2A, GADA and/or ICA) at 1 month were considered autoantibody-positive. Patients with an absence of autoantibodies (IA-2A, GADA and/or ICA) at 1 month were considered autoantibody-negative.

ICA were detected by indirect immunofluorescence using commercial Primate Pancreas slides from INOVA. The sera were screened at a dilution of 1:2 and FITC-labelled anti-human IgG (Dako, Copenhagen, Denmark) was used as conjugate and grouped as negative 0-0.5 U.

GADA were quantified by a direct radioimmuassay (Diamyd Diagnostics, Stockholm, Sweden). Sera were run in duplicate, and the results were read on a gamma counter (Wizard 1470; Wallac/PerkinElmer, Turku, Finland) and calculated from a standard curve. The cut-off limit was 10 U/ml, set from a comparison between 94 patients with type 1 diabetes and 98 healthy blood donors. The intra- and interassay coefficients of variation were 2.9% and 5.1%, respectively (12).

IA-2A were analyzed with a radiobinding assay (13). The results were expressed as relative units (RU) based on a standard curve run on each plate using an automated calculation program (MultiCalc; Wallac). The limit for IA-2A positivity (0.77 RU) was set at the 99th percentile in 374 non-diabetic children and adolescents. The inter-assay coefficient of variation was \< 12%. IA were measured by a modification of the method described by Williams et al. (14), the cut-off limit for positivity was 2.80 RU.

Residual beta-cell function
---------------------------

Mixed-meal stimulated serum C-peptide was used as a marker of residual β-cell function after a disease duration of 1, 6, and 12 months. Serum samples were labeled and frozen at - 20 °C until shipment on dry ice for the determination of C-peptide within half a year.

Serum C-peptide was analyzed by a fluoroimmunometric assay (AutoDELFIATM C-peptide, Perkin Elmer Life and Analytical Sciences, Inc, Turku, Finland). The analytical sensitivity was better than 5 pmol/l, the intra-assay coefficient of variation was \<6% at 20 pmol/l, and recovery of standard, added to plasma before extraction, about 100% when corrected for losses inherent in the plasma extraction procedure. Total proinsulin-immunoreactivity was analyzed by a two-site ELISA based on the monoclonal antibodies coating antibody PEP-001 and detecting antibody HUI-001 (Novo Nordisk A/S, Bagsværd, Denmark). The sensitivity was below 0.3 pmol/l.

Genotyping
----------

Typing of the HLA-class II *DRB1*locus was performed by direct sequencing of exon 2 of *DRB1*according to the Immuno Histocompatibility Working Group. *DR 03/04*and *DR 04/04*were defined as high-risk genotypes, while *DR 03/03*and *DR 04/08*were considered to convey moderate risk. All other genotypes were classified as low-risk. The analysis of the variable number of tandem repeats region of the insulin gene (*INS-VNTR*) was performed as previously described by Nielsen et al. (15) We sequenced coding exons and flanking intronic regions of the genes *HNF1A*(16), *HNF4A*(17)*, INS*(18) and *KCNJ11*(5). All 39 exons, flanking intron and non-coding 5\' and 3\' untranslated regions of *ABCC8*were sequenced by a high-throughput, semi-automated strategy as decribed by Sandal et al. (19).

Functional analysis
-------------------

For functional analysis, we coexpressed wild-type or mutant SUR1 together with wild-type Kir6.2 in *Xenopus laevis*oocytes, as previously described (6). Whole-cell currents were recorded using a 2-electrode voltage-clamp in response to voltage steps of ± 20 mV from a holding potential of -10 mV, in a solution containing (in mM): 90 KCl, 1 MgCl~2~, 1.8 CaCl~2~, 5 HEPES (pH 7.4 with KOH). Metabolic inhibition was induced by 3 mM Na-azide, and 0.5 mM tolbutamide was used to block K~ATP~channels, as indicated. Data were analysed with pCLAMP8 (Axon Instruments, CA, USA), Origin 6.02 (Microcal Software, Northampton, MA, USA) and Igor (Wavemetrics, Lake Oswego, OR, USA) software and are given as mean+SEM. Statistical significance was evaluated using an unpaired two-tailed Student\'s t-test. A probability value of P \< 0.05 was considered a significant difference.

Statistical methods
-------------------

C-peptide, and proinsulin were investigated by means of the logarithmic scale. C-peptide, proinsulin, blood glucose change, insulin dose, HbA~1c~and IDAA1c were analysed by multiple regression with age, sex, and antibody status (negative/positive) as explanatory variables in a compound symmetric repeated measurement model. A *P*-value \< 0.05 was considered significant. Statistical analyses were performed using SAS version 9.1 (SAS Institute, USA, Inc, Cary, NC, USA).

Results
=======

Twenty-four patients (9.1%, Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) out of 261 tested negative for GADA, IA-2A, and ICA after 1 month. Of these, 22 were also negative at 6 and 12 months after diagnosis, whereas one of the patients seroconverted to positivity at six months (IA-2A) and another at 12 months (GADA). The group of 22 patients remaining autoantibody-negative (Table1) did not differ significantly from the autoantibody-positive group with respect to sex (*P*= 0.40), age (*P*= 0.49), ethnicity (*P*= 0.80,), HLA risk groups (p = 0.68) or *INS-VNTR*genotypes. Autoantibody-negative patients had lower titers of Insulin Antibodies at 1 month after diagnosis (*P*= 0.01), not shown. Six of 22 (27%) autoantibody-negative patients had first-degree relatives with diabetes compared with 22 of 237 autoantibody-positive subjects (10%) (*P*= 0.01) indicating that genetic factors may be of predominant importance. None of the 6 autoantibody-negative patients with a family history of diabetes had mutations in *HNF1A*or *HNF4A*. There were no *INS*gene mutations in the autoantibody negative group.

###### 

Clinical characteristics of the 22 study participants who remained negative for autoantibodies: GADA, IA-2A, and ICA 1, 6, and 12 months after diagnosis of type 1 diabetes

  Patient   Age    Sex      BMI (kg/m^2^)   HbA1C 0 (%)   IDAA1C 1   IDAA1C 6   IDAA1C 12   Ins dose1 (U/kg/day)   ins dose6 (U/kg/day)   Ins dose12 (U/kg/day)   Cpep1 (pmol/L)   Cpep6 (pmol/L)   Cpep12 (pmol/L)   BGstim1 (mmol/L)   BGstim6 (mmol/L)   BGstim12 (mmol/L)
  --------- ------ -------- --------------- ------------- ---------- ---------- ----------- ---------------------- ---------------------- ----------------------- ---------------- ---------------- ----------------- ------------------ ------------------ -------------------
  1         16.3   female   31.14           11.8          Na         7.1        6.8         0.33                   0.22                   0.33                    1055             201              272               14.33              10                 9.1
                                                                                                                                                                                                                                                            
  3         6.6    female   14.31           6.3           Na         Na         7.3         Na                     Na                     0.22                    416              79               208               8.7                7.5                10.6
                                                                                                                                                                                                                                                            
  4         14.2   female   14.9            12.8          11.5       8.5        10          0.24                   0.22                   0.51                    902              617              735               8.9                11.4               15.9
                                                                                                                                                                                                                                                            
  6         6.7    male     12.8            9.1           10.2       8.1        8.7         0.33                   0.3                    0.46                    392              413              277               13.7               14.5               11.4
                                                                                                                                                                                                                                                            
  7         1.4    male     13.7            11.1          10.3       8.2        10.6        0.25                   0.23                   0.5                     184              67               21                13.2               13.4               15.6
                                                                                                                                                                                                                                                            
  9         7      male     14.26           9             9.2        9.4        11.7        0.33                   0.38                   0.74                    18               21               13                8.9                10.2               8.4
                                                                                                                                                                                                                                                            
  10        10.8   female   17.6            10.4          10.6       8.4        8.6         0.63                   0.49                   0.56                    592              472              320               11.1               19.9               20.7
                                                                                                                                                                                                                                                            
  11        14.2   female   15.1            14.2          15.6       10.9       10.8        1.10                   0.77                   0.71                    411              347              291               15.6               18.7               20.7
                                                                                                                                                                                                                                                            
  12        4.7    female   15.7            9.3           11.1       8.2        9.4         0.71                   0.52                   0.6                     238              299              212               7.8                11.7               18.3
                                                                                                                                                                                                                                                            
  14        14.1   male     31.6            12            10.1       6.4        6.5         0.18                   0.1                    0.1                     1353             1517             1147              6.2                5.8                5.0
                                                                                                                                                                                                                                                            
  15        3.6    male     11.5            15.3          13.2       9.8        13.7        0.44                   0.39                   0.84                    479              380              216               10.1               Na                 Na
                                                                                                                                                                                                                                                            
  16        11.2   male     16.4            10.9          11.7       7.1        8.0         0.63                   0.2                    0.41                    577              294              590               10.3               7.2                9.2
                                                                                                                                                                                                                                                            
  17        3      female   17.72           8.3           8.6        7.4        7.1         0.39                   0.3                    0.57                    379              252              2721              8.7                5.7                11.4
                                                                                                                                                                                                                                                            
  18        6.3    female   17.2            9.3           9.5        Na         7.8         0.48                   0.41                   0.38                    417              886              495               9.4                12.3               11.7
                                                                                                                                                                                                                                                            
  19        11.3   female   14.4            13.2          12.5       10.8       11.1        0.70                   0.94                   0.89                    514              376              437               14.7               10.7               12.7
                                                                                                                                                                                                                                                            
  20        14     male     19.4            13            12.5       7.4        11.3        0.52                   0.37                   0.44                    374              272              615               10.3               8.9                16.3
                                                                                                                                                                                                                                                            
  21        3.1    male     14.4            11            9.9        9.0        Na          0.25                   0.45                   0.75                    91               101              183               12.5               17.7               19.2
                                                                                                                                                                                                                                                            
  22        3.1    male     14.4            8.6           9.3        9.8        11.0        0.35                   0.41                   0.64                    309              229              176               15.0               18.0               19.9
                                                                                                                                                                                                                                                            
  23        10.5   male     17.3            14.3          Na         11.7       13.0        0.91                   1.0                    1.4                     312              210              156               10.4               14.4               15.7
                                                                                                                                                                                                                                                            
  25        11.1   female   Na              13            11.3       11.7       13.0        0.90                   1.0                    1.44                    292              628              450               7.1                11.1               12.9
                                                                                                                                                                                                                                                            
  26        11.1   female   27.4            10.2          10.9       7.3        7.6         0.52                   0.57                   0.5                     2040             1226             701               6.9                6.3                4.1
                                                                                                                                                                                                                                                            
  27        8.8    female   Na              9             9.4        8.5        10.1        0.30                   0.31                   0.69                    596              482              318               9.4                23.6               20.3
                                                                                                                                                                                                                                                            
  Mean      8.4             16.9            11.0          10.9       8.9        9.9         0.49                   0.47                   0.64                    518.4            436.6            489.6             10.4               12.5               14.0
                                                                                                                                                                                                                                                            
  SD        4.2             4.9             2.4           1.7        1.6        2.1         0.24                   0.27                   0.32                    448.6            375.8            577.5             2.7                5.1                5.1

Abbreviations: SD, standard deviation; Na, not available; BMI, body mass index; HBA1C0, HBA1C at diagnosis; IDAA1C 1, Insulin Dose Adjusted HbA1c (IDAA1C) at 1 month; IDAA1C 6, IDAA1C at 6 months; IDAA1C 12, IDAA1C at 12 months; Ins dose1, insulin dose at 1 month; Ins dose6, insulin dose at 6 months; Ins dose12, insulin dose at 12 months; Cpep1, stimulated C-peptide at 1 month, Cpep6, stimulated C-peptide at 6 months; Cpep12, stimulated C-peptide at 12 months; BGstim1, 90 min glucose at 1 month; BGstim6, 90 min glucose at 6 months; BGstim12, 90 min glucose at 12 months

###### 

Clinical characteristics of the two study participants who tested negative for autoantibodies (GADA, IA-2A, and ICA) at 1 month and who converted to positivity for GADA (patient 2) at 12 months or IA-2A (patient 24 (carrier of the Arg1530Cys mutation of the ABCC8)) at 6 and 12 months after the diagnosis of type 1 diabetes

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Age\      Sex      BMI\        HbA1C0\   IDAA1C 1   IDAA1C 6   IDAA1C 12   Ins dose1\   ins dose6\   Ins dose12\   Cpep1\     Cpep6\     Cpep12\    BGstim1\   BGstim6\   BGstim12\
            (years)            (kg/m^2^)   (%)                                         (U/kg/day)   (U/kg/day)   (U/kg/day)    (pmol/L)   (pmol/L)   (pmol/L)   (mmol/L)   (mmol/L)   (mmol/L)
  --------- --------- -------- ----------- --------- ---------- ---------- ----------- ------------ ------------ ------------- ---------- ---------- ---------- ---------- ---------- -----------
  2         16.3      female   17          10.9      Na         11.1       11.7        0.54         0.73         0.59          120        10         10         14.2       20.7       13.2

                                                                                                                                                                                      

  24        14        male     16.4        12.4      11.3       10.6       12.8        0.63         0.73         0.98          356        308        218        13.9       21         20.6
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Na, not available; BMI, body mass index; HBA1C0; HBA1C at diagnosis; IDAA1C 1, Insulin Dose Adjusted HbA1c (IDAA1C) at 1 month; IDAA1C 6, IDAA1C at 6 months; IDAA1C 12, IDAA1C at 12 months;; Ins dose1, insulin dose at 1 month; Ins dose6, insulin dose at 6 months; Ins dose12, insulin dose at 12 months; Cpep1, stimulated C-peptide at 1 month, Cpep6, stimulated C-peptide at 6 months; Cpep12, stimulated C-peptide at 12 months; BGstim1, 90 min glucose at 1 month; BGstim6, 90 min glucose at 6 months; BGstim12, 90 min glucose at 12 months;

Better residual beta-cell function and glycemic control in autoantibody-negative subjects
-----------------------------------------------------------------------------------------

The residual beta-cell function (as assessed by meal-stimulated C-peptide) in the 22 persistently autoantibody-negative patients was twice as high as in autoantibody-positive patients 12 months after diagnosis (*P*= 0.005, Fig. [1A](#F1){ref-type="fig"}), and the proinsulin values were correspondingly higher in autoantibody-negative patients (*P*= 0.01, Fig. [1B](#F1){ref-type="fig"}). Moreover, the autoantibody-negative patients experienced lower blood glucose changes (2.4 mmol/L) during the Boost test at 12 months of follow-up (*P*= 0.004, Fig. [1C](#F1){ref-type="fig"}). During the 12 months follow-up glycemic control was significantly better in autoantibody-negative patients as they had 0.65% (absolute) lower HbA~1c~than autoantibody-positive subjects (*P*= 0.04, data not shown). In terms of insulin requirement, the autoantibody-negative patients received 0.15 IU/kg/day less insulin 12 months after diagnosis compared with autoantibody-positive subjects (*P*= 0.02) (Fig. [1D](#F1){ref-type="fig"}). Twelve months after diagnosis, autoantibody-negative children had on an average 1.25% (absolute) lower insulin dose adjusted HbA1c (IDAA1c) than autoantibody-positive children (*P*= 0.005) (Fig. [1E](#F1){ref-type="fig"}).

![**Comparison of disease course in autoantibody-negative and autoantibody-positive children**: *A*: 12 months after disease onset, the residual beta cell function in autoantibody-negative patients was twofold higher than in autoantibody-positive patients (p = 0.002). *B*: Autoantibody-negative patients had significantly higher proinsulin release 12 months after disease diagnosis than autoantibody-positive subjects (*P*= 0.01). *C*: The blood glucose change (90 minutes value minus fasting value) during meal-stimulation differed significantly between autoantibody-negative and autoantibody-positive patients 12 months after disease onset (*P*= 0.004). *D*: 12 months after diagnosis autoantibody-negative patients received about 0.15 IU/kg/day less insulin than autoantibody-positive subjects (*P*= 0.02). *E*: Autoantibody-negative subjects had 0.8% lower IDAA1c than autoantibody-positive patients (*P*= 0.02).](1472-6823-10-16-1){#F1}

Mutation in *ABCC8*
-------------------

We screened both the *KCNJ11*and *ABCC8*genes in all 24 subjects negative for autoantibodies (IA-2A, GADA and/or ICA) at one month after diagnosis. None had a mutation in *KCNJ11*. However, we identified a novel heterozygous mutation in *ABCC8*: a C \> T change leading to a predicted Arg \> Cys substitution at codon 1530 of SUR1 (Table [2](#T2){ref-type="table"}) in one subject. This amino acid residue is conserved from zebrafish to humans and is located in the second nucleotide-binding domain of SUR1, a region previously implicated in neonatal diabetes.

We studied the functional effects of the SUR1-R1530C mutation by expressing recombinant K~ATP~channels in *Xenopus*oocytes. Wild-type K~ATP~channels are normally closed when expressed in *Xenopus*oocytes due to the high intracellular ATP concentration, but they are activated by metabolic inhibitors such as azide, which lower ATP (Fig. [2](#F2){ref-type="fig"}). In contrast, in oocytes expressing SUR1-R1530C mutant channels significant resting whole-cell K~ATP~currents were present in the absence of metabolic inhibition (Fig. [2](#F2){ref-type="fig"}). Thus, basal cellular metabolism causes less block of mutant K~ATP~channels than wild-type channels. Mutant channel currents were increased by 3 mmol/l azide, indicating that they can be further activated by metabolic inhibition. Importantly, mutant channels were blocked by 0.5 mmol/l tolbutamide (Fig. [3](#F3){ref-type="fig"}), a concentration that fully saturates the high-affinity-binding site for sulfonylureas. There was no difference in the potency of block for wild-type and mutant channels: 91 ± 3% (n = 4) *v*84 ± 7% (n = 4) respectively (Fig. [3](#F3){ref-type="fig"}).

![**Tolbutamide response in SUR1-R1530C**. Whole-cell currents recorded from Xenopus oocytes coexpressing Kir6.2 and either SUR1 (WT) or SUR1-R1530C in response to voltage steps of +20 mV from a holding potential of -10 mV. Bars indicate the times of application of 3 mmol/l azide or 0.5 mmol/l tolbutamide.](1472-6823-10-16-2){#F2}

![**Tolbutamide response in SUR1-R1530C**. Mean steady-state whole-cell K-ATP currents (as indicated) evoked by a voltage step from -10 to -30 mV before (rest; grey bars) and after application of 3 mmol/l azide (grey bars) and in the presence of 3 mmol/l azide plus 0.5 mmol/l tolbutamide (black bars). Four oocytes were used for each experiment. \*P \< 0.05against control (t-test).](1472-6823-10-16-3){#F3}

The patient and first-degree relatives
--------------------------------------

The patient with the *ABCC8*mutation was 13 years old when diagnosed (Table [2](#T2){ref-type="table"}). He had a high risk HLA profile (DR 04/04) and became positive for IA-2A 6 months after diagnosis. He had no first-degree relatives with diabetes. The mother was negative for the mutation in the *ABCC8*gene and the father was unavailable for mutation analysis. Although functional analyses showed that the mutant channel was highly sensitive to sulfonylureas, there was no clinical effect on metabolic control or insulin requirement after four weeks of glibenclamide treatment (1.0-1.2 mg/kg/24h) 8 years after diagnosis of diabetes. We believe that the patient developed T1 D in addition to the *ABCC8*-diabetes as he now is insulin-dependent, C-peptide- and IA-2A-negative but GADA-positive (14.9 U/ml, cut-off limit is 10 U/ml) and therefore had no beneficial effects of sulphonylurea treatment. Meal-stimulated GLP-1 and GIP did not differ between the subject carrying the R1530C mutation and non-carriers (data not shown).

Discussion
==========

This study shows that 9,1% of children and adolescents with newly diagnosed type 1 diabetes did not have autoantibodies for ICA, GADA and IA-2A on initial testing or on 12 months follow-up (Table [1](#T1){ref-type="table"}). This is consistent with a recent study on children and adolescents by Rubio-Cabezas where 9,9% tested negative for the same pancreatic autoantibodies(20)

We find that, when investigated in a physiologic setting, residual beta-cell function was considerably improved in autoantibody-negative (GADA, ICA, IA-2A) children with T1 D compared with autoantibody-positive (GADA, ICA, IA-2A) T1 D one year after diagnosis (Fig. [1A,B](#F1){ref-type="fig"}). The patients also had better glycemic control and required less exogenous insulin underscoring the milder disease process in patients with autoantibody-negative T1 D (Fig. [1C,D,E](#F1){ref-type="fig"}). We measured autoantibodies at 1, 6, and 12 months after diagnosis, and since we had no measurement at diagnosis, theoretically we cannot rule out the possibility that some patients might have been autoantibody positive at diagnosis and during the first month experienced seroconversion to antibody-negativity. On the other hand, none of the 239 subjects who were autoantibody-positive at one month converted to autoantibody-negative within the 12 months after diagnosis. We decided to exclude IA from our definition of autoantibody negativity, because we did not measure autoantibodies at onset. We do not think this biased our study, as at disease presentation very few patients are positive for insulin autoantibodies only (21). However, in the present study autoantibody-negative patients also had lower titers of IA at 1 month after diagnosis, further underscoring a lower immunological response and milder disease progression in this group of patients.

Recently it has been established that presence of autoantibodies directed against the beta cell zinc transporter ZnT8 are associated with type 1 diabetes. We have not included ZnT8 antibodies in our study but in a recent study in adults 1.4% of the GADA and IA-2A negative patients were ZNT8 positive (22). Therefore in future studies the inclusion of ZnT8 AB is mandatory to differentiate clinical phenotypes.

In our study we did not find any association with antibody (ICA, GADA, IA-2A) status and HLA risk alleles. It is possible that this could be explained by the absence of ZnT8 antibody status in the present study, and that inclusion of these might have revealed such an association.

Our findings indicate that a positive family history of diabetes may play a role, not related to the classical T1 D loci (HLA and *INS-VNTR)*. An important question is whether the 22 patients who remained autoantibody-negative truly had T1 D. At study entry the diagnosis of diabetes mellitus was made according to the WHO recommendations, and the responsible clinician at each center established the diagnosis of T1 D by her/his clinical judgment. Patients with suspected type 2 diabetes and patients with a family history of diabetes in three consecutive generations and with onset before the age of 25 years (suspected monogenic diabetes) were excluded. In the 6 antibody-negative patients with a positive family history, we did not find any mutations in *HNF1A*or *HNF4A*. We did not screen patients without a family history of diabetes for mutations and do not think we overlooked monogenic diabetes in these patients as spontaneous mutations are rare, although not impossible, in the transcription factor MODY genes (15, 17, 23, 24). On the other hand, neonatal diabetes due to mutations in *INS*(4, 17, 25) or either of the genes encoding the K-ATP subunits KIR6.2 (5) and SUR1 (6, 7) occurs *de novo*in approximately 50% of the cases and these subjects typically present with autoantibody-negative insulin-dependent diabetes. Relevant for the present study is our recent observation that *INS*mutations can be a cause of antibody-negative diabetes presenting as T1 D (18). Thus, we regarded *INS*, *KCNJ11*and *ABCC8*being good candidate genes in our antibody-negative patients.

We did not find pathogenic mutations in *INS*or *KCNJ11*, but one subject had a heterozygous mutation (R1530C) in SUR1 encoded by *ABCC8*. We believe this mutation is pathogenic because: (1) arginine at codon 1530 is conserved through evolution from zebrafish to humans; (2) codon 1530 is located in the second nucleotide-binding domain of SUR1, and other mutations in this domain cause permanent and transient neonatal diabetes and (3) functional analysis showed that homozygous mutant channels were \~three-fold more active at rest than wild-type channels. This suggests that the K-ATP current magnitude will also be increased in the beta-cell and in the heterozygous state, and can explain the diabetes of the patient.

Although our functional analyses showed that the channel was highly sensitive to sulphonylureas, our patient (8 years after diagnosis of diabetes) did not benefit from glibenclamide after 4 weeks of treatment (1.0-1.2 mg/kg/24h) in terms of metabolic control and insulin requirement. The 13-year-old male patient seroconverted to IA-2A positivity 6 months after diagnosis. It has been shown that adult-onset diabetes caused by SUR1 mutations responds favorably to sulphonylurea treatment (26). A possible explanation for the unsuccessful sulphonylurea treatment in our patient, despite promising functional studies of the K-ATP-channel, might be that the patient developed autoimmune diabetes. He had a high risk HLA profile, which might also facilitate the progression to autoimmune diabetes.

Conclusions
===========

In conclusion GADA, IA-2A, and ICA-negative children with T1 D have slower disease progression including better preservation of β-cell function and improved glycaemic control 12 months after diagnosis. A mutation within the *ABCC8*gene may be a, so far, unidentified cause of autoantibody-negative childhood-onset diabetes, also after the neonatal period.
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